34 reports

Major players in the kidney cancer drugsmarket are Bayer AG, Pfizer Inc., Novartis International AG, Exelixis Inc., F.Hoffmann-La Roche Ag, Genentech Inc., Glaxosmithkline Plc., Active Biotech, Amgen, Thermo Fisher Scientific Inc., Bristol-Myers Squibb, Eisai, Roche, Cipla Limited, Onyx, Abbott Laboratories, Aveo Pharmaceuticals, Immatics...

  • Renal Cancer
  • World
  • United States
  • Middle East
  • APAC
  • Biologics Penetration Rate
  • Tobacco Consumption

Kidney Cancer Therapeutics & Diagnostics market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Kidney Cancer Therapeutics & Diagnostics Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Kidney Cancer Therapeutics...

  • Diagnostics
  • Renal Cancer
  • Therapy
  • World

The kidney cancer therapeutics & diagnostics market will show a rapid growth due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies. - According to the GLOBOCAN, the incidence of Kidney cancer is 4.5 per 100,000 in 2018, worldwide. The 5 major countries contributing to the global...

  • Renal Cancer
  • Cancer
  • Diagnostics
  • Targeted Therapy
  • APAC
  • Europe
  • Africa
  • Smoking Prevalence
  • Cause-Specific Mortality Rate

Major players in the kidney cancer drugs market are Bayer AG, Pfizer Inc., Novartis International AG, Exelixis, Inc., and F. Hoffmann-La Roche Ag. The global kidney cancer drugs market is expected to decline from $3.3 billion in 2020 to $3.29 billion in 2021 at a compound annual growth rate (CAGR) of -0.3%. The slow decline is mainly...

  • Renal Cancer
  • World
  • United States
  • APAC
  • Biologics Penetration Rate
  • Tobacco Consumption

Kidney Cancer (Renal Cell Cancer) (Oncology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) – Drugs In Development, 2021, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape. Kidney...

  • Renal Cancer
  • World

Kidney Cancer Therapeutics & Diagnostics Market Report Overview Kidney Cancer Therapeutics & Diagnostics market size outlook report provides comprehensive coverage of market landscape including strategic growth areas, unique insights, and major trends across Kidney Cancer Therapeutics & Diagnostics market types and applications. It is a...

  • Diagnostics
  • Renal Cancer
  • Therapy
  • World
  • Health Provider Density

Abstract: - Global Kidney Cancer Drugs Market to Reach $6.4 Billion by 2027 - Amid the COVID-19 crisis, the global market for Kidney Cancer Drugs estimated at US$4.9 Billion in the year 2020, is projected to reach a revised size of US$6.4 Billion by 2027, growing at aCAGR of 3.8% over the period 2020-2027. Targeted...

  • Renal Cancer
  • World
  • China
  • United States

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer - Pipeline Review, H1 2020, provides an overview of the Kidney Cancer (Oncology) pipeline landscape. Kidney cancer also called renal cancer...

  • Renal Cancer
  • World

KEY FINDINGS The global kidney cancer therapeutics and diagnostics market is projected to register a CAGR of 5.52% during the forecast period, 2019-2028. The factors propelling the growth of the market are estimated to be the rising usage of minimally invasive processes, increasing research & development expenditure, and...

  • Renal Cancer
  • World

Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H1, 2020 Summary clinical trial report, “Kidney Cancer (Renal Cell Cancer) Global Clinical Trials Review, H1, 2020" provides an overview of Kidney Cancer (Renal Cell Cancer) Clinical trials scenario.This report provides top line...

  • Clinical Trial
  • Renal Cancer
  • World

Carbonic Anhydrase 9 - Pipeline Review, H2 2019 Summary According to the recently published report ’Carbonic Anhydrase 9 - Pipeline Review, H2 2019’; Carbonic Anhydrase 9 (Carbonate Dehydratase IX or pMW1 or Membrane Antigen MN or P54/58N or Renal Cell Carcinoma Associated Antigen G250 or CA9 or...

  • Renal Cancer
  • Pharmaceutical
  • World
  • Japan
  • Europe
  • Diagnostic Imaging Density
  • Drug Approval

Renal Cell Carcinoma: Epidemiology Forecast to 2028 Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, which is part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC...

  • Renal Cancer
  • World
  • Cancer Incidence
  • Smoking Prevalence

A recent market study published on the gamma probe devices market offers a global industry analysis for 2016-2020 and an opportunity assessment for 2021-2031. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the...

  • Clinic
  • Breast Cancer
  • Renal Cancer
  • World

Community Oncology Services Market Global Report 2020-30: Covid 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global community oncology services market. This report focuses on community oncology services market which is experiencing strong growth....

  • Clinic
  • Skin Cancer
  • Marketing Research
  • Lung Cancer
  • Breast Cancer
  • Ovarian Cancer
  • Colorectal Cancer
  • Liver Cancer
  • Prostate Cancer
  • Renal Cancer
  • Pancreatic Cancer
  • World

KEY FINDINGS The North America kidney cancer therapeutics and diagnostics market is predicted to project a CAGR of 5.59% during the forecast period, 2019-2028. The growing number of kidney cancer cases and the collective efforts of the organizations are set to influence the market growth in the region. MARKET...

  • Renal Cancer
  • Therapy
  • North America
  • Canada

KEY FINDINGS The Asia Pacific kidney cancer therapeutics and diagnostics market is estimated to project a CAGR of 5.92% during the forecast period, 2019-2028. The growing awareness, along with the rising R&D activities, is set to propel the growth of the market in the region. MARKET INSIGHTS Indonesia,...

  • Renal Cancer
  • APAC
  • Tobacco Consumption

KEY FINDINGS The Europe kidney cancer therapeutics and diagnostics market is projected to showcase a CAGR of 5.36% during the forecast period, 2019-2028. The advanced healthcare system in the countries of the region is set to result in immense growth opportunities for the market under study. MARKET INSIGHTS The...

  • Renal Cancer
  • Diagnostics
  • Europe
  • France
  • Cause-Specific Mortality Rate

“Endothelial PAS domain-containing protein 1 inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Endothelial PAS domain-containing protein 1 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers...

  • Therapy
  • Renal Cancer
  • World
  • Drug Approval

This study covers the world outlook for kidney cancer-treating drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These...

  • Renal Cancer
  • World
  • Gross Domestic Product
  • Disposable Income

Renal Cell Carcinoma: Global Drug Forecast and Market Analysis to 2028 Summary Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, making up 90-95% of all kidney cancer cases.Globally, RCC represents the sixth most frequently diagnosed cancer in men and 10th in women. RCC...

  • Renal Cancer
  • Therapy
  • United States
  • China
  • Japan
  • World
  • Cancer Incidence
  • Smoking Prevalence

Kidney Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Targeted Therapy, Immunotherapy), By Pharmacologic Class, By Country, And Segment Forecasts, 2016 - 2022 The global kidney cancer drugs market size is expected to be valued at USD 6.3 billion by 2022, as per a new report by Grand View Research, Inc.,...

  • Cancer
  • Renal Cancer
  • World
  • United States
  • APAC
  • Elderly Population
  • Cancer Incidence

Summary Peloton Therapeutics Inc (Peloton) is a clinical-stage pharmaceutical company that develops oral medicines and novel therapies for oncology.Its portfolio of pipeline products includes PT2977, PT2567 and PT2385. The company develops its products for the treatment of pulmonary arterial hypertension, solid tumors,...

  • Therapy
  • Renal Cancer
  • Pharmaceutical
  • Healthcare
  • United States
  • Health Provider Density

Renal cell carcinoma (RCC), also known as kidney cancer or renal adenocarcinoma, is the most common type of kidney cancer in adults. It occurs at an average age of 64 years. RCC is a disease which develops in the lining of the kidney tubules and grows into a mass or tumor. It accounts for approximately 3 percent of adult malignancies and 90...

  • Renal Cancer
  • United States
  • World
  • Drug Approval
  • Health Expenditure

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2017, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline...

  • Renal Cancer
  • World

Renal cell carcinoma (RCC), also known as kidney cancer or renal adenocarcinoma, is the most common type of kidney cancer in adults, occurring at an average age of 64 years. It is a disease which develops in the lining of the kidney tubules and grows into a mass or tumor. It accounts for approximately 3% of adult malignancies and...

  • Renal Cancer
  • Pharmaceutical
  • United States
  • Drug Approval
  • Cancer Mortality

Summary NovioGendix Holding BV (NovioGendix), a subsidiary of MDxHealth SA is a biotechnology company that offers molecular diagnostic research and service. The company develops clinically useful molecular diagnostic assays for the uro-oncological diseases. Its projects under clinical trial development include prostate cancer, bladder...

  • Cancer
  • Molecular Diagnostics
  • Renal Cancer
  • Medical Equipment
  • Pharmaceutical
  • Bladder Cancer
  • Clinical Trial
  • Biotechnology
  • Prostate Cancer
  • Research Center
  • APAC
  • Europe
  • North America
  • Middle East
  • Africa

Renal Cell Carcinoma - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Renal Cell Carcinoma – Pipeline Review, H2 2016, provides an overview of the Renal Cell Carcinoma (Oncology) pipeline landscape. Renal cell carcinoma (RCC, formerly known...

  • Renal Cancer
  • World

EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023 Summary Renal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. RCC is the most...

  • Renal Cancer
  • Epidemiology
  • United States
  • Japan
  • World
  • Urban Population
  • Cancer Incidence

Summary TVAX Biomedical, Inc. (TVAX) is a biotechnology company that develops cell-based immunotherapy for treatment of cancer. The company uses proprietary combination of cancer cell vaccination with killer T cell treatment. Its TVI-Brain-1 is a drug therapy used for the treatment of brain cancer. TVAX is also developing therapy...

  • Pharmaceutical
  • Immunotherapy
  • Clinical Trial
  • Brain Cancer
  • Biotechnology
  • Cell Therapy
  • Renal Cancer
  • Oncology
  • Healthcare
  • APAC
  • North America
  • Europe
  • Middle East
  • Africa

Renal cell cancer

4385 5000 3900

Despite the approvals of several pipeline therapies, the renal cell cancer (RCC) market is expected to experience only moderate growth due to market saturation and the expiries of key brand patents. This report addresses the following questions: - What factors are contributing to the increase in RCC incidence across the...

  • Renal Cancer
  • United States
  • Japan
  • European Union
  • Smoking Prevalence
  • Drug Approval